DiaceuticsFRA:7DC +1.23%90 Days Payable is 53.77 as of Dec. 2025, which is 6% below its 10-year median of 57.48. GuruFocus rates FRA:7DC with a GF Score™ of 90/100 and a GF Value™ of €2.13 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 607 Healthcare Providers & Services companies, Diaceutics ranks better than 55.85% on this metric.
Diaceutics's average Accounts Payable for the
six
months ended in Dec. 2025 was €1.51 Mil. Diaceutics's Cost of Goods Sold for the
six
months ended in Dec. 2025 was €5.12 Mil.
Hence, Diaceutics's Days Payable for the
six
months ended in Dec. 2025 was 53.77.
The historical rank and industry rank for Diaceutics's Days Payable or its related term are showing as below:
FRA:7DC'
s Days Payable Range Over the Past 10 Years
Min: 15.29 Med: 57.48 Max: 107.12
Current: 66.92
During the past 10 years, Diaceutics's highest Days Payable was 107.12. The lowest was 15.29. And the median was 57.48.
FRA:7DC's Days Payable is ranked better than 55.85% of 607
companies
in the Healthcare Providers & Services industry
Industry Median: 58
vs FRA:7DC: 66.92
Diaceutics's Days Payable
declined
from Dec. 2024 (71.99) to Dec. 2025 (53.77).
It may suggest that Diaceuticsaccelerated paying its suppliers.
Diaceutics Days Payable Related Terms
Diaceutics Days Payable Historical Data
* Premium members only.
The historical data trend for Diaceutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7DC vs VEEV, BTSG, TEM: Days Payable Comparison
For the Health Information Services subindustry, Diaceutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diaceutics Days Payable vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Diaceutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Diaceutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Diaceutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diaceutics (FRA:7DC) has a Days Payable of 53.77 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Diaceutics and its competitors. This is near median its historical median of 57.48. Over the past decade, Diaceutics' Days Payable has ranged from 15.29 to 107.12. According to the industry distribution chart, Diaceutics ranks #268 out of 607 companies in the Healthcare Providers & Services industry, placing it in the top 44.2%.
Is Diaceutics' Days Payable too high?
Diaceutics' current Days Payable of 53.77 is near median its 10-year median of 57.48. Over the past 10 years, this metric has ranged from a low of 15.29 to a high of 107.12. The Healthcare Providers & Services industry median Days Payable is 58.00. Diaceutics' value of 53.77 is 7.3% below this industry median. Based on the distribution chart, Diaceutics ranks #268 out of 607 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Diaceutics has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diaceutics' Days Payable compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Diaceutics ranks #268 out of 607 companies for Days Payable. This puts Diaceutics in the upper half of its industry. The industry median Days Payable is 58.00. Diaceutics' value of 53.77 is 7.3% below this benchmark. Historically, Diaceutics' own Days Payable has ranged from 15.29 to 107.12 over the past decade. While the company's 10-year median is 57.48 vs. the industry median of 58.00, Diaceutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Healthcare Providers & Services company?
The median Days Payable among Healthcare Providers & Services companies is 58.00, based on 607 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diaceutics's current Days Payable of 53.77 is 7.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Diaceutics and its competitors. For the Healthcare Providers & Services industry, the median Days Payable is 58.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diaceutics's current Days Payable is 53.77, which is near median its own 10-year median of 57.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diaceutics stock overvalued right now?
Based on GuruFocus' analysis, Diaceutics (FRA:7DC) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.13, compared to a current price of €1.64 — trading 23% below its estimated fair value. The current Days Payable is 53.77, which is near median its 10-year median of 57.48 and 7.3% below the Healthcare Providers & Services industry median of 58.00. Diaceutics' overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Diaceutics (FRA:7DC), the current Days Payable is 53.77 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diaceutics (FRA:7DC) Overvalued in 2026?
Based on GuruFocus' analysis, Diaceutics stock appears to be undervalued.
The current stock price of €1.64 is trading 23% below its estimated GF Value™ of €2.13.
GuruFocus considers Diaceutics to be Modestly Undervalued.
Key valuation signals for FRA:7DC:
Days Payable: 53.77 (near median its 10-year median of 57.48)
GF Value™: €2.13 vs. price of €1.64 (23% below fair value)
Industry Position: 7.3% below the Healthcare Providers & Services median (#268 of 607)
No single metric tells the full story. See the FRA:7DC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides integrated commercialization solutions that help biopharma companies maximize patient access, accelerate uptake, and improve the lifetime value of their therapies. The group's services span the full commercial lifecycle, from pre-launch ideas through to mature brand optimization, delivered through an integrated combination of data, technology, and expertise. Its DXRX Data Solutions include DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, and DXRX Disease Testing Rate Tracker. Geographical market by customer location in the UK, North America, Europe, Asia, and the rest of the world.
90GF Score
Get the complete analysis for FRA:7DC
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7DC has been successfully added to your 
